New cholesterol combo drug passes early safety check in 60 volunteers
NCT ID NCT06858865
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This early-stage study tested a new drug called AD-228A in 60 healthy adults to see how the body absorbs and processes it. The drug is designed to lower high cholesterol. Participants received a single dose of the new drug or a combination of two existing drugs to compare safety and drug levels. The study is complete, but results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H+ Yangji Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.